Sign In
Buy NBTX
$38.39
-1.77 (-4.41%)
At Close: Jul 31, 2026
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
04:15pm, Monday, 13'th Nov 2023
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 mo
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
04:15pm, Thursday, 09'th Nov 2023
Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET
NANOBIOTIX Announces Closing of Global Offering
04:01pm, Tuesday, 07'th Nov 2023
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pion
PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pion
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
10:49am, Thursday, 02'nd Nov 2023
PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pion
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
06:32pm, Wednesday, 01'st Nov 2023
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pion
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
06:30pm, Wednesday, 01'st Nov 2023
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pion
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile
Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript
10:52am, Wednesday, 27'th Sep 2023
Nanobiotix S.A. (NASDAQ:NBTX ) Q2 2023 Earnings Conference Call September 27, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder & CEO Bart Van Rhijn - CFO Conference
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
04:15pm, Tuesday, 19'th Sep 2023
Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
04:15pm, Thursday, 31'st Aug 2023
PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-ba
Nanobiotix: At A Crucial Juncture For Data
08:40am, Thursday, 24'th Aug 2023
Nanobiotix is an oncology-focused biotech aiming for its first drug approval, with a tripled value since the beginning of 2023. Their flagship molecule, NBTX3-RT, is showing promising results in enhan
Nanobiotix surges on commercialization deal with J&J's Janssen for cancer therapeutic
01:11pm, Monday, 10'th Jul 2023
French biotechnology company Nanobiotix has entered into an agreement with J&J's wholly-owned medical research and pharmaceutical arm Janssen to license, co-develop and commercialize a drug to treat h
Nanobiotix ADRs Jump Over 50% After Agreement With J&J's Janssen Pharmaceutical
10:40am, Monday, 10'th Jul 2023
American depositary receipts of Nanobiotix jumped over 50% in early trading on Monday after signing an agreement with J&J's Janssen Pharmaceutical to work on co-developing a drug to treat head and nec
Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica
06:14am, Monday, 10'th Jul 2023
Shares of Nanobiotix SA NBTX, +1.57% shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology company announced a global licensing and co-development agre
